Artivion amends agreements with endospan

Provides endospan with $25 million of additional debt funding to obtain fda approval for nexus upfront payment associated with purchase option reduced to $135 million, inclusive of loan off-set, and $100 million earnout minimum eliminated  atlanta , july 1, 2024 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced it has amended its credit facility and option purchase agreements with endospan ltd. ("endospan"), an israeli-based, privately-held developer of the nexus® stent graft system ("nexus").
AORT Ratings Summary
AORT Quant Ranking